Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Idiosyncratic drug hepatotoxicity represents a major problem in drug development due to inadequacy of current preclinical screening assays, but recently established rodent models utilizing bacterial LPS co-administration to induce an inflammatory background have successfully reproduced idiosyncratic hepatotoxicity signatures for certain drugs. However, the low-throughput nature of these models renders them problematic for employment as preclinical screening assays. Here, we present an analogous, but high-throughput, in vitro approach in which drugs are administered to a variety of cell types (primary human and rat hepatocytes and the human HepG2 cell line) across a landscape of inflammatory contexts containing LPS and cytokines TNF, IFNγ, IL-1α, and IL-6. Using this assay, we observed drug-cytokine hepatotoxicity synergies for multiple idiosyncratic hepatotoxicants (ranitidine, trovafloxacin, nefazodone, nimesulide, clarithromycin, and telithromycin) but not for their corresponding non-toxic control compounds (famotidine, levofloxacin, buspirone, and aspirin). A larger compendium of drug-cytokine mix hepatotoxicity data demonstrated that hepatotoxicity synergies were largely potentiated by TNF, IL-1α, and LPS within the context of multi-cytokine mixes. Then, we screened 90 drugs for cytokine synergy in human hepatocytes and found that a significantly larger fraction of the idiosyncratic hepatotoxicants (19%) synergized with a single cytokine mix than did the non-hepatotoxic drugs (3%). Finally, we used an information theoretic approach to ascertain especially informative subsets of cytokine treatments for most highly effective construction of regression models for drug- and cytokine mix-induced hepatotoxicities across these cell systems. Our results suggest that this drug-cytokine co-treatment approach could provide a useful preclinical tool for investigating inflammation-associated idiosyncratic drug hepatotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 2×
“A doi:10.1016/j.taap.2009.04.002 Please cite this article as: Cosgrove, B.D. et study of inflammation-associated idiosyncr a b s t r a c t a r t i c l e i n f o”
BackgroundInfluentialLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Pharmaco-metabonomic phenotyping and personalized drug treatment
Andrew Clayton, T., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le Net, J.-L., Baker, D., Walley, R. J., et al. (2006) · Nature · doi:10.1038/nature04648 · Cited by 824
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Liu, S., Gallo, D. J., Green, A. M., Williams, D. L., Gong, X., Shapiro, R. A., Gambotto, A. A., Humphris, E. L., Vodovotz, Y., & Billiar, T. R. (2002) · Infection and Immunity · doi:10.1128/iai.70.7.3433-3442.2002 · Cited by 246
Human hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242
Metformin prevents endotoxin-induced liver injury after partial hepatectomy
Bergheim, I., Luyendyk, J. P., Steele, C., Russell, G. K., Guo, L., Roth, R. A., & Arteel, G. E. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092122 · Cited by 75
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationIn vitro models for liver toxicity testing
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013) · Toxicol. Res. · doi:10.1039/c2tx20051a · Cited by 472
Self-citationKostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., & Roth, A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.012 · Cited by 262
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow
Esch, M. B., Prot, J.-M., Wang, Y. I., Miller, P., Llamas-Vidales, J. R., Naughton, B. A., Applegate, D. R., & Shuler, M. L. (2015) · Lab on a Chip · doi:10.1039/c5lc00237k · Cited by 173
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Trovafloxacin toxicity, in particular, was sensitive to lipopolysaccharide (LPS)–mediated stimulation of Kupffer macrophages, a finding consistent with other studies in 2D monolayers.(128) While the consistency in size distribution of the microtissues is impressive (i.”
Result
Metadata
- Authors
- Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., & Lauffenburger, D. A.
- Venue
- Toxicology and Applied Pharmacology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 237
- Issue
- 3
- Pages
- 317-330
- ISSN
- 0041-008X (ISSN-L)
- OpenAlex
- W2049789320
- Cited by
- 136
- References
- 9
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. https://app.cochat.ai/papers/10.1016/j.taap.2009.04.002
- The paper
- Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., Griffith, L. G., Sorger, P. K., Tidor, B., Xu, J. J., & Lauffenburger, D. A. (2009). Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2009.04.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.